Jorey Chernett, who already holds a ten percent ownership stake in Neuronetics, Inc., executed a notable purchase of the company's common stock on May 19, 2026. This recent transaction involved acquiring 100,000 shares at a price point of $1.17 per share, totaling $117,000 in value.
Following this direct acquisition, Chernett's total holdings of Neuronetics common stock increased to 10,553,988 shares. The timing of this insider purchase is noteworthy, given that the company’s stock has been trading near $1.20 and has seen a decline of 72% over the previous year.
The reported activity suggests an internal view that may differ from recent market performance. Analysis available through InvestingPro indicates that Neuronetics currently appears undervalued at its existing price levels, a perspective that aligns with Chernett's decision to increase his personal stake in the company.
Company Developments and Financial Context
Neuronetics Inc. recently disclosed its financial results for Q1 2026. The report detailed a revenue figure of $34.5 million, which surpassed the consensus analyst expectation of $34.18 million. Despite this positive performance in top-line growth, the company failed to meet its earnings per share (EPS) forecast. Specifically, Neuronetics recorded a loss of $0.16 per share, compared to the anticipated loss of $0.13.
These financial results present a mixed picture: revenue demonstrated upward momentum, yet this growth was partially offset by missing analyst projections for EPS. Further operational updates highlight efforts to enhance technological capability and efficiency within the firm's core business areas.
A key development is Neuronetics' announcement of a collaboration with ANT Neuro. This partnership is designed to integrate neuronavigation technology into the company’s NeuroStar Advanced Therapy System. The integration will specifically incorporate ANT Neuro’s visor2 neuronavigation system, which provides real-time spatial tracking and 3D visualization capabilities for treatment delivery.
This strategic alliance aims to significantly improve both the precision and overall effectiveness of treatments delivered through transcranial magnetic stimulation methods. Industry observers and investors are closely monitoring these advancements as they could potentially impact Neuronetics' future operational performance and market standing.
Analysis of Market Signals
The combination of insider buying, which signals strong internal belief in the company's value, alongside substantial technological partnerships provides a complex narrative for stakeholders. While the Q1 2026 earnings showed robust revenue growth ($34.5 million beating $34.18 million), the simultaneous EPS miss (loss of $0.16 vs. expected loss of $0.13) introduces a layer of caution.
The focus on integrating advanced neuronavigation technology through the ANT Neuro partnership underscores an ongoing commitment to improving treatment efficacy and technical execution within the medical device sector. The market's reaction, therefore, will likely hinge on how these technological enhancements translate into sustainable financial improvements that positively affect the bottom line.